Better clinical outcome of total knee arthroplasty for rheumatoid arthritis with perioperative glucocorticoids and disease-modifying anti-rheumatic drugs after an average of 11.4-year follow-up

Yi Ren†, Qi Yang†, Tim Luo‡, Jin Lin, Jin Jin, Wenwei Qian, Xisheng Weng† and Bin Feng‡

Abstract

Background: Previous evidence suggested that perioperative anti-rheumatic therapy for patients receiving total knee arthroplasty (TKA) helped improve postoperative rehabilitation for rheumatoid arthritis (RA), yet long-term effects and outcomes of perioperative drug therapy in TKA presently remain unclear. This study investigated whether perioperative treatment with glucocorticoids (GC) and disease-modifying anti-rheumatic drugs (DMARDs) can improve clinical outcomes for patients with RA undergoing TKA.

Methods: Patients between January 2000 and December 2011 were allocated into three groups based on perioperative drug therapy: A, control group (no GC or DMARDs), B, DMARD group (DMARDs given without GC), and C, co-therapy group (DMARDs plus GC). The patients were followed up for average 11.4 years. Baseline characteristics, pre- and post-operative Hospital for Special Surgery score (HSS), laboratory parameters, and complications were recorded by follow-up.

Results: Fifty-six RA patients undergoing 91 TKAs were included in this study. Patients who received perioperative GC with DMARDs (group C) achieved larger/increased range of motion (ROM) (C:122.17 vs A:108.31 vs B:108.07, \(p = 0.001\), partial eta squared (\(\eta^2\)) = 0.18) at 1 year, better HSS score (C, 83.01 vs A, 79.23 vs B, 77.35, \(p = 0.049\), \(\eta^2\) = 0.067), pain relief (C, 1.09 vs A, 1.17 vs B, 1.75, \(p = 0.02\), \(\eta^2\) = 0.094), and ROM (C, 130.81 vs A, 112.82 vs B, 113.58, \(p = 0.001\), \(\eta^2\) = 0.142) at latest follow-up comparing with the other treatment groups. No differences were noted in laboratory tests, blood loss, volume of transfusion, or complications among groups.

(Continued on next page)
Conclusions: Compared with the other perioperative anti-rheumatic treatments, the combination of GC and DMARDs results in improved HSS score, better function, larger range of motion, and reduced postoperative pain for TKA patients with RA in the long term. Further investigation is warranted to look for a better understanding of more specific medication effects and strike a good balance between the benefits and complications for long-term pharmacotherapy.

Keywords: Total knee arthroplasty, Rheumatoid arthritis, Disease-modifying anti-rheumatic drugs, Glucocorticoids, Clinical outcome, Complication

Introduction

Rheumatoid arthritis (RA) is often characterized as an inflammatory autoimmune disease, causing cartilage and bone damage with progression to joint malformation and eventual loss of function. Knee lesions are commonly seen in chronic RA patients, gradually impairing ambulatory capacity and subsequent quality of life [1–3].

For end-stage knee arthropathy of RA patients, total knee arthroplasty (TKA) is an effective approach to achieve outstanding restoration of knee function. However, it is still an open question how anti-rheumatic medication management should be designed perioperatively. Orthopedic surgeons should weigh the balance between risk of infection and flare during arthroplasty surgery. According to conventional practice and international consensus, it is suggested that the continuation of anti-rheumatic drug therapy (except for biologic agents) helps control disease activity and improve postoperative rehabilitation [4]. Previous literature reported that perioperative use of glucocorticoids (GC) and disease-modifying anti-rheumatic drugs (DMARDs) contribute to a lower disease activity level in 1 year after surgery, avoiding exacerbation of the disease, measured by Disease Activity Score including 28-joint count (DAS28) [5]. However, clinical data of long-term effects of perioperative drug therapy in TKA presently remain sparse. This study intends to evaluate short-term and long-term clinical outcome and postoperative complications associated with preoperative GC and DMARD use in RA patients undergoing TKA surgery.

Materials and methods

This is a retrospective observational study designed under the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines and was approved by the institutional review board [6] (number of approval: S-K1025). Informed written consents were obtained from patients for publication.

Patient selection and management

The process of patient selection is shown in flow chart (Fig. 1). To reach a long-term follow-up result, patients included in our study should (1) be diagnosed with RA undergoing TKAs between January 2000 and December 2011; (2) receive treatment with DMARDs or DMARDs plus GC in curative dose for a minimum of 1 year continuously after surgery, or just without anti-rheumatic medication; (3) agree to participate in our study and follow-up. Exclusion criteria included (1) diagnosis with other joint diseases (i.e. osteoarthritis, ankylosing spondylitis); (2) disobedience to receive anti-rheumatic medication treatment continuously in the 1 year postoperatively; (3) patients who declined to be followed up or could not provide complete data.

RA disease status was verified in all patients through history of rheumatologist diagnosis according to standardized diagnostic criteria before admission. The enrolled patients underwent cemented TKA with posterior stabilized prosthesis through medial parapatellar approach. Surgical techniques and the type of prostheses were decided by attending surgeons. Patients received thromboprophylaxis with subcutaneous injection of low-weighted molecular heparin (nadroparin calcium, 0.4 ml, q.d.; or enoxaparin sodium, 0.4 ml, q.d.) in a total of 7–14 days depending on their walking ability and coagulation function after surgery. Sequential compression devices began within 24 h of operation for thromboembolic prophylaxis and continued during the hospitalization period.

Based on perioperative anti-rheumatic medication therapy, patients were organized into three treatment groups:

A. Control group (no anti-rheumatic drugs used)
B. DMARD group (conventional or biologic DMARD use with no GC)
C. Co-therapy group (DMARD and GC use)

In group A, the disease was treated and controlled with immunosuppressants before. The immunosuppressants were stopped after consultation with their attending physicians. Therefore, no further anti-rheumatic drugs were used during the perioperative period. Non-steroid anti-inflammatory drugs (NSAIDs) were
administered if necessary. Follow-up was then conducted through outpatient clinic questionnaires or via telephone. The patients were regularly followed at postoperative 3 months, 1 year, and annually thereafter. In summary, the follow-up of the patients ranged from 7–16 years after surgery, with an average of 11.4 years.

In our study, no patients received GC monotherapy. Conventional DMARDs treatment was continued during surgery for groups B and C; however, all biologic DMARDs were stopped 4 weeks before surgery and restarted at least 1 week postoperatively depending on medication, wound healing, and disease status. Oral NSAIDs were given in each group as needed to control acute pain.

**Data extraction and collection**

Data in our study came from our database and the outpatient-clinic follow-up. Information on patient demographics included age, gender, body mass index (BMI), information regarding NSAIDs, GC and DMARD therapy, the type of prothesis for each operated knee and whether unilateral or bilateral TKA was performed (Tables 1 and 2).

For clinical evaluation, Hospital of Special Surgery (HSS) knee score, ROM were recorded preoperatively, at the time of 1 year and latest follow-up. The pain was further assessed using a visual analog scale (VAS). Preoperative DAS28 was also recorded. Laboratory test involved white blood cells (WBC), hemoglobin (HGB), C reaction protein (CRP), erythrocyte sedimentation rate (ESR), and rheumatoid factor (RF). The volume of wound drainage, need for postoperative blood transfusion, the postoperative temperature at days 1 and 3 (T pod 1 and 3) were involved for analysis. The total perioperative blood loss was calculated based on the "hemoglobin balance" theory [7].

Short-term complications within 3 months postoperatively, such as acute infection, delayed wound healing, and RA flare, were recorded and were categorized into
systematic, wound, and surgical issues. Long-term complications related to the index operation were also recorded/noted down, such as periprosthetic joint infection (PJI), fracture, prosthesis loosening, and need for surgical revision.

Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics software version 25 (IBM Corporation, Armonk, USA). Continuous data with normal distribution were reported as mean and standard deviation (SD), while non-normally distributed data were presented as median and interquartile range. Analysis of variance (ANOVA) was used to compare quantitative data among the three treatment groups with subsequent Bonferroni pairwise comparisons. Kruskal-Wallis test was indicated for non-normally distributed data. Considering that disease activity might affect the value of pain evaluation, HSS scoring, and ROM, we adopted DAS28 as a covariate of these results and used analysis of covariance method. Besides, partial eta squared ($\eta^2_p$) was employed for calculating effect size with the following cut-off values to interpret 0.01 to 0.06 as small effect, 0.06 to 0.14 as medium effect, and above 0.14 as large effect. Chi-square test and Fisher’s exact test were used to analyze qualitative variables. In Fisher’s exact test, Bonferroni

### Table 1 Patient demographics

|                  | Group A | Group B | Group C | p value |
|------------------|---------|---------|---------|---------|
| Number of patients (n) | 20      | 15      | 21      | /       |
| Number of knees (n)    | 29      | 26      | 36      | /       |
| Number of operated knees (unilateral/bilateral) (n) | 11/9   | 4/11    | 6/15    | /       |
| Age (years)            | 53.91 ± 11.02 | 53.51 ± 11.11 | 48.21 ± 11.94 | 0.88 |
| BMI (kg/m²)            | 23.42 ± 2.86  | 22.52 ± 3.84  | 22.12 ± 4.24  | 0.40   |
| Sex (female/male) (n)  | 14/6    | 13/2    | 18/3    | 0.35   |
| DAS28                 | 2.56 ± 0.63  | 2.68 ± 0.43  | 2.36 ± 0.63  | 0.09   |
| Duration of medication treatment after surgery(years) N/A | 8.13 ± 2.42 | 8.33 ± 2.63 | 0.80   |
| Pre-op HSS            | 43.61 ± 16.32 | 42.02 ± 14.32 | 42.01 ± 17.73 | 0.91 |
| Pre-op ROM (°)        | 78.51 ± 34.79 | 78.73 ± 30.82 | 89.81 ± 28.22 | 0.25 |
| Pre-op pain           | 4.96 ± 0.96  | 4.65 ± 1.02  | 3.48 ± 0.87  | 0.06   |
| Pre-op function       | 18.28 ± 7.11 | 18.85 ± 7.79 | 18.00 ± 9.09 | 0.92   |
| Pre-op VAS            | 5.93 ± 0.59  | 6.37 ± 0.63  | 6.76 ± 0.53  | 0.12   |
| Pre-op WBC (*10⁹/L)   | 6.75 ± 1.81  | 7 ± 1.92     | 7.05 ± 2.58  | 0.88   |
| Pre-op HGB (g/L)      | 119.12 ± 17.09 | 111.21 ± 14.22 | 116.22 ± 28.22 | 0.34 |
| Pre-op CRP (mg/L) #   | 4.5 (1.6–15.3) | 15.0 (4.0–27.9) | 8.5 (1.7–25.9) | 0.18   |
| Pre-op ESR (mm/h) #   | 27.0 (12.0–64.0) | 58.0 (38.5–78.0) | 32.0 (14.5–65.3) | 0.06   |
| Pre-op RF (U/ml) #    | 39.0 (10.4–106.0) | 64.0 (28.0–189.5) | 31.2 (10.7–131.3) | 0.32   |

n case number, TKA total knee arthroplasty, BMI body mass index, DAS28 Disease Activity Score 28-joint, Pre-op preoperative, HSS Hospital for Special Surgery score, ROM range of motion, VAS visual analog scale, WBC white blood cell, HGB hemoglobin, CRP C-reaction protein, ESR erythrocyte sedimentation rate, RF rheumatoid factor, N/A not applicable

* Data were described as “median (interquartile range)” with Kruskal-Wallis test

### Table 2 Perioperative medications in groups B and C

| No. of cases | Median dosage | Median treatment duration |
|--------------|---------------|--------------------------|
| Group B      |               |                          |
| LEF          | 5             | 15 mg daily 8 years      |
| MTX          | 9             | 12.5 mg weekly 10 years |
| SASP         | 1             | 2000 mg daily 5 years    |
| TGP          | 1             | 1200 mg daily 0.5 years  |
| TG           | 7             | 40 mg daily 14 years     |
| ETN          | 2             | 25 mg biweekly 0.5 years |
| Group C      |               |                          |
| IGU          | 2             | 50 mg daily 1 year       |
| MTX          | 18            | 12.5 mg daily 12 years   |
| PA           | 1             | 1000 mg daily 6 years    |
| SASP         | 1             | 2000 mg daily 4 years    |
| TG           | 13            | 60 mg daily 8 years      |
| ETN          | 3             | 25 mg biweekly 0.5 years |
| PRDL         | 4             | 7.5 mg daily 11.5 years  |
| PRED         | 16            | 10 mg daily 12 years     |
| MPS          | 1             | 8 mg bi daily 21 years   |

LEF leflunomide, MTX methotrexate, TGP total glucosides of paony, TG tripterygium glycosides, SASP salicylazosulfapryridine, ETN etanercept, IGU iguratimod, PA penicillamine, PRDL prednisolone, PRED prednisone, MPS methylprednisolone
correction was used for adjusting the significance limit to $P < 0.017$, while significance was defined as $P < 0.05$ for other tests.

Results

Demographic and disease features

This study included 91 TKA operations performed on 56 RA patients in our hospital, with a mean patient age of 51.7 years. The mean duration of RA medication treatment after surgery was approximately 8 years for both groups B and C. No statistically significant difference was seen between any treatment groups in patient demographics, preoperative or postoperative laboratory tests, estimated blood loss, and temperature at POD1 (Tables 1 and 3). There was no significant difference of disease activity status for the three groups after evaluation with DAS28.

Type, dose, and duration of anti-rheumatic medication

The patients accepted non-selective (Diclofenac Sodium, Ibuprofen) or selective Cox-2 inhibitor (celecoxib) treatment for pain control when necessary. No statistical difference was observed in terms of the proportion of non-selective or selective NSAIDs use ($P = 0.82$). In group B, the 15 patients were treated with conventional DMARDs as a single drug regimen. Eight of them (53.3%) accepted treatment with total glucosides of paeyony (TGP) or tripterygium glycosides (TG), which is known as anti-rheumatic drugs extracted from plants. Two patients in group B (13.3%) were given a mix of conventional and biologic DMARD. All patients in group C received GC plus DMARDs, among whom 20 patients (95.2%) received conventional DMARD monotherapy and 13 of the 20 patients received TGP. One patient (4.8%) received the combination therapy with two conventional DMARDs, and three patients (14.3%) received a mix of biologic and conventional DMARD regimen. No patients received GC intra-articular injections. (Table 2)

Outcome measurements

Statistical analysis showed no significant difference among patients in three groups in terms of VAS ($P = 0.34$) and treatment for pain control when necessary. No statistical difference was observed in terms of the proportion of non-selective or selective NSAIDs use ($P = 0.82$). In group B, the 15 patients were treated with conventional DMARDs as a single drug regimen. Eight of them (53.3%) accepted treatment with total glucosides of paeyony (TGP) or tripterygium glycosides (TG), which is known as anti-rheumatic drugs extracted from plants. Two patients in group B (13.3%) were given a mix of conventional and biologic DMARD. All patients in group C received GC plus DMARDs, among whom 20 patients (95.2%) received conventional DMARD monotherapy and 13 of the 20 patients received TGP. One patient (4.8%) received the combination therapy with two conventional DMARDs, and three patients (14.3%) received a mix of biologic and conventional DMARD regimen. No patients received GC intra-articular injections. (Table 2)

Table 3 Postoperative clinical outcomes and clinical outcomes during perioperative period, at the 1-year and latest follow-up

|                | Group A | Group B | Group C | p    | A vs B | A vs C | B vs C |
|----------------|---------|---------|---------|------|--------|--------|--------|
| Perioperative period |         |         |         |      |        |        |        |
| Drainage (ml)# | 500.0(320.0–640.0) | 430.0(330.0–730.0) | 540.0(265.0–833.5) | 0.98 | /      | /      | /      |
| Blood transfusion(ml) # | 400.0(0–600.0) | 600.0(300.0–800.0) | 600.0(400.0–800.0) | 0.16 | /      | /      | /      |
| Post-op WBC (*10³/L) | 10.63 ± 3.72 | 11.87 ± 3.81 | 11.91 ± 3.2 | 0.34 | 0.68   | 0.60   | 0.99   |
| Post-op HGB (g/L) | 106.57 ± 5.40 | 97.59 ± 6.31 | 98.59 ± 5.48 | 0.06 | 0.11   | 0.13   | 1.00   |
| HGB drop (g/L) | 17.83 ± 14.51 | 14.91 ± 11.16 | 24.39 ± 18.23 | 0.13 | 0.99   | 0.44   | 0.17   |
| Estimated blood loss (ml)# | 762.96 (359.29–1282.42) | 743.58 (524.72–1341.36) | 818.95 (601.09–1104.66) | 0.72 | /      | /      | /      |
| T pod 1 (°C) | 37.94 ± 0.39 | 37.82 ± 0.64 | 37.59 ± 0.72 | 0.20 | 0.99   | 0.23   | 0.99   |
| T pod 3 (°C) | 37.52 ± 0.29 | 37.21 ± 0.63 | 37.09 ± 0.51 | 0.03 | 0.48   | 0.02** | 0.85   |
| Post-op ROM before discharge (°) | 100.21 ± 5.86 | 108.43 ± 6.26 | 108.05 ± 5.33 | 0.08 | 0.17   | 0.15   | 1.00   |
| At the 1-year follow-up |         |         |         |      |        |        |        |
| ROM (*) | 108.31 ± 5.37 | 108.07 ± 5.75 | 122.17 ± 4.89 | 0.001 | 1.00   | 0.001** | 0.001*** |
| VAS | 2.24 ± 0.68 | 2.71 ± 0.76 | 2.24 ± 0.73 | 0.34 | 0.48   | 1.00   | 0.42   |
| HSS | 72.22 ± 2.36 | 70.91 ± 2.52 | 74.88 ± 2.14 | 0.06 | 1.00   | 0.30   | 0.06   |
| HSS pain score | 22.79 ± 2.43 | 22.43 ± 2.56 | 23.23 ± 2.01 | 0.78 | 1.00   | 1.00   | 1.00   |
| HSS function score | 13.72 ± 1.43 | 12.84 ± 1.53 | 14.34 ± 1.30 | 0.34 | 1.00   | 1.00   | 0.43   |
| At the latest follow-up |         |         |         |      |        |        |        |
| ROM (*) | 112.82 ± 7.82 | 113.58 ± 8.36 | 130.81 ± 7.12 | 0.001 | 1.00   | 0.003** | 0.008*** |
| VAS | 1.17 ± 0.43 | 1.75 ± 0.52 | 1.09 ± 0.39 | 0.02 | 0.10   | 1.00   | 0.04*** |
| HSS | 79.23 ± 3.31 | 77.35 ± 3.53 | 83.01 ± 3.01 | 0.049 | 1.00   | 0.27   | 0.045** |
| HSS pain score | 25.67 ± 2.37 | 24.52 ± 2.68 | 26.75 ± 2.47 | 0.15 | 0.82   | 0.73   | 0.12   |
| HSS function score | 14.60 ± 1.66 | 13.71 ± 1.77 | 15.56 ± 1.51 | 0.30 | 1.00   | 1.00   | 0.36   |

Post-op postoperative, HSS Hospital for Special Surgery, ROM range of motion, VAS visual analog scale, WBC white blood cell, HGB hemoglobin, T pod 1/T pod 3, temperature in postoperative days 1 and 3

*Difference between groups A and B is significant
** Difference between groups A and C is significant
*** Difference between groups B and C is significant

#Data were described as “median (interquartile range)” with Kruskal-Wallis test
HSS pain score ($P = 0.78$) at the 1-year follow-up. At the latest follow-up, the patients in group C showed significant improvement in VAS score compared with those in group B ($P = 0.04$, $\eta^2_p = 0.094$), but no statistical difference in HSS pain score ($P = 0.12$). There was no statistical difference when comparing group A with group B or C in terms of VAS and HSS pain score (Table 3).

At the postoperative 1-year follow-up, patients in group C had an increased degree of ROM than the other two groups ($p = 0.001$ and 0.001, $\eta^2_p = 0.18$). At the latest follow-up, patients in group C also had the significantly greater improvement of ROM compared with both groups A and B ($p = 0.003$ and $p = 0.008$ respectively, $\eta^2_p = 0.142$), while there was no difference of ROM between groups A and B at the latest follow-up ($p = 1.00$) (Table 3).

There was no statistical significance of HSS knee score among three groups at the postoperative 1 year ($p = 0.06$) (Table 3). At the latest follow-up, patients in group C had significantly higher HSS score than patients in group B ($p = 0.045$, $\eta^2_p = 0.067$) (Table 3), while there was no significant difference of HSS score between group A and B ($p = 1.00$) as well as groups A and C ($p = 0.27$) (Table 3 and Fig. 2).

Postoperative complication
The details of complications were shown in Table 4. For short-term complication, there was no complication of DVT in group C, while one in group A and four in group B. The DVT ratio in group C was lower than that in group B, and pairwise comparison showed no statistical significance between the two groups ($p = 0.03$). As for other short-term complication, there was no difference of systematic, wound, and surgical complication among the three groups.

After average 11.4 years follow-up, no aseptic loosening, instability, or periprosthetic fracture was reported in our study. One case developed prosthetic joint infection (PJI) in group C at 3 years after index surgery and underwent two-stage revision surgery.

Discussion
Rheumatoid arthritis is an inflammatory autoimmune disease causing progressive articular destruction and malformation. GC and DMARD managements are routinely used to control chronic RA disease activity. Anti-inflammatory glucocorticoids are commonly used to reduce pain, stiffness, and to slow progressive bone erosion [3, 8, 9]. DMARDs is another cornerstone class of RA medication, consisting of conventional and biologic DMARDs, which slows disease progression by targeting and resolving inflammatory disease pathophysiology. The combination of GC and DMARDs provides additive benefit and is reported to reduce the risk for joint replacement and radiographic disease progression compared with drug monotherapy [4, 10, 11]. TKA remains
the definitive treatment in end-stage disease with severe malformation, which can restore joint function [12, 13].

Inflammatory control and suppression of RA disease activity are critical to TKA perioperative management according to the American College of Rheumatology/American Association of Hip and Knee Surgeons 2017 Guideline. When RA patients underwent elective TKA, it was recommended to continue the current dose of conventional DMARDs, but to withhold all current biologic agents prior to surgery. Once the wound shows evidence of healing and no non-surgical site infections occur, the biologic therapy should be resumed [14]. In this study, we aimed to observe the long-term clinical outcome of perioperative anti-rheumatic medication use in TKA surgery.

It was reported that the intervention of anti-rheumatic drugs could improve the short-term clinical outcome and patient satisfaction [15]. Results of the present study also showed that perioperative treatment with DMARDs and GC co-therapy could result in significant long-term improvement in HSS score, VAS score, and patient satisfaction compared with patients managed with only DMARDs, and corresponding effect sizes were characterized from medium to large effect. The possible reason was that both GC and DMARDs could exert synergetic effect to lower perioperative disease activity. Goodman et al. reviewed the availability and safety of anti-rheumatic medications in perioperative treatment [16]. Systematic GC use was regarded effective to accelerate recovery, functional rehabilitation after arthroplasty surgery among RA patients through its pain-relieving and anti-emetic effect shortly after surgery [1, 13]. On the other side, administration of DMARDs can mitigate soft tissue damage, reduce inflammation, and therefore improve joint symptoms by interfering with complex immune pathways in the pathogenesis of RA, especially in the long run [17–19]. Therefore, the combination of these two kinds is conducive to functional improvement from the short to long term.

We also found ROM significantly increased in co-therapy group than either DMARDs-only or no anti-rheumatics groups in short- and long-term follow-up. These results agree with previous literature supporting treatment with GC combined with DMARDs to achieve better patient satisfaction and prognosis [1, 13, 17–20]. We found no significant difference in HSS score, VAS pain, or ROM was observed between patients given DMARD alone and the control group. Possible reason might be that pain from other joints damaged by systemic RA may interfere with the assessment of knee joints after TKA surgery, without the rapid onset of GC analgesic effects [21, 22]. Furthermore, the NSAIDs used in group B could also inhibit inflammation shortly after surgery, so did GC. Overall, this study supports the co-therapy of perioperative DMARD and GC to improve knee function, patient satisfaction, and decrease pain.

We also reported DVT events in our three cohorts, with one case in the control, four in the DMARD therapy group, and no cases in the GC and DMARDs co-therapy group. DVT is a common complication after TKA procedure. With the use of GC, the morbidity rate increases, mainly due to an induced hypercoagulable state [23]. White et al. reported perioperative GC therapy for patients undergoing spinal surgery had an increased risk of DVT than those without GC therapy [23]. Continuing systematic use of GC rendered higher risk of venous thromboembolism with an approximate 2-fold increase [24]. But the impact of GC use for patients receiving TKA still remained unclear. The result of study might indicate no increase in DVT risk associated with co-therapy use among RA patients in the long term. Nevertheless, risk evaluation should be performed carefully for individuals before decision.

Although our study shows GC and DMARDs to improve joint function, mobility, and patient satisfaction with limited complication, RA patients are still at particular risk for infection, either systemic or local [8]. Prosthetic joint infection (PJI) is a form of local infection, occurs in about 0.5–2% of TKAs and is a disastrous surgical complication after TKA [4, 25, 26]. A meta-analysis describes increased risk for PJI up to 3 years postoperatively in patients using continuous GC therapy.

Table 4 Complications during follow-up

|                          | Group A | Group B | Group C | P     | A vs B | A vs C | B vs C |
|--------------------------|---------|---------|---------|-------|--------|--------|--------|
| Deep venous thrombosis (cases) | 1       | 4       | 0       | 0.03  | 0.14   | 1.00   | 0.03   |
| Number of other short-term complications§ | 4†      | 0       | 4 †     | 0.15  | /      | /      | /      |
| Systematic              | 2       | 0       | 3       | 0.36  | /      | /      | /      |
| Wound                   | 1       | 0       | 0       | 0.99  | /      | /      | /      |
| Surgical                | 1       | 0       | 1       | 0.99  | /      | /      | /      |
| Long term               | 0       | 0       | 1       | 0.63  | /      | /      | /      |

† Included allergic shock after blood transfusion; hemarthrosis; subcutaneous adiponecrosis and common peroneal nerve compression; sciatic nerve injury
‡ Included urinary infection; herpes zoster; compromised sensory function of planta pedis and plantar flexion ability of the first toe; thrombocytopenia
§ Short-term complications are defined as those no more than 3 months after surgery
There is also a correlation between the intra-articular injection of GC and PJI after knee arthroplasty [27]. Nevertheless, perioperative inflammatory damage of RA disease can potentially cause periarticular bone degradation and implant loosening [2, 28, 29]. Studies have also suggested that a standard dose of GC peroperatively can help with inflammation without drastically increasing infectious risk during the surgical period [30]. Only one case of PJI developed at 3 years follow-up in our entire study, and occurred in the GC and DMARD co-therapy group. According to our study, it is very difficult to draw any sound conclusion about the GC treatment for RA patients and the development of PJI.

Limitations are inevitable in all studies including this one. First, the study cohort was relatively small, as all patient profiles were acquired from the database of a single medical center. Although we were able to draw conclusions from our study, and patients we selected were over 11.4 years follow-up which have covered the breadth of conventional RA presentations, a larger population may provide greater statistical efficacy and may permit a more comprehensive analysis of surgical complications. Second, many different types of conventional and biologic DMARDs were analyzed in combination, which potentially may mask specific medication affects. However, more detailed categorizing and analysis of patient drug regimens would have required a much larger study population and combined analysis of DMARDs allow our study results to be better reflected and applied to a heterogeneous general RA population. Third, approximately half of our patients contributed two knees in our study. Even though we separately analyzed under several outcomes such as HSS and ROM, lack of the interaction data between two knees might lead to the loss of statistical power and an increase in potential biases when interpreting results. Fourth, we did not evaluate the side-effect of long-term use of GC treatment, such as osteoporosis, and gastric-intestinal side-effect. Future study is needed to answer this concern. The clinicians should balance the benefit and the complication for long-term GC treatment in practice. Finally, our long-term analysis period with an average 11.4-year follow-up inevitably contributed to cohort attrition due to death or an inability or refusal to follow-up, which further limited our study size. And the medical information we obtain from their close relatives is rarely as accurate as the patient’s self-reported history.

In conclusion, this study suggests that perioperative co-pharmacotherapy with GC and DMARDs, compared with the other treatments, can better improve long-term TKA clinical outcomes and knee recovery measured through HSS knee score, joint ROM, and VAS pain, while does not increase the surgical-related complications. Further investigation is warranted with a larger cohort size to have a better understanding of more specific medication effects and strike a good balance between the benefits and complications for long-term co-pharmacotherapy.

**Abbreviations**

TKA: Total knee arthroplasty; RA: Rheumatoid arthritis; GC: Glucocorticoids; DMARD: Disease-modifying anti-rheumatic drug; ROM: Range of motion; HSS: Hospital for Special Surgery; STROBE: Strengthening the Reporting of Observational Studies in Epidemiology; VAS: Visual analog scale; DAS-28: Disease Activity Score including 28-joint count; WBC: White blood cells; HGB: Hemoglobin; CRP: C-reaction protein; ESR: Erythrocyte sedimentation rate; RF: Rheumatoid factor; DVT: Deep vein thrombosis; POD: Postoperative day

**Acknowledgements**

Not applicable.

**Authors’ contributions**

YR and QY performed research, collected, analyzed, and interpreted data and drafted and wrote the manuscript. JL, JJ, and WQ performed the surgery and supervised data collection and critically reviewed the paper. BF and TL revised the manuscript. XW and BF designed research and supervised data collection. All authors read and approved the final manuscript.

**Funding**

This research work received grants and was financially supported by the National Nature Science Foundation in China (No. 81871740)

**Availability of data and materials**

The datasets generated and/or analyzed during the current study are not publicly available due to the local policy but are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board in Peking Union Medical College Hospital (IRB number: S-K1025). All participants signed informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no competing financial interest about the work.

**Author details**

1Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, China. 2Department of Orthopedics, First Hospital of Harbin, Harbin, China. 3Department of Medicine Program, University of Alberta, Edmonton, AB, Canada.

Received: 17 October 2020 Accepted: 14 January 2021
Published online: 27 January 2021

**References**

1. Koh IJ, Chang CB, Lee JH, Jeon YT, Kim TK. Preemptive low-dose dexamethasone reduces postoperative emesis and pain after TKA: a randomized controlled study. Clin Orthop Relat Res. 2013;471:3010–20.
2. LoVerde ZJ, Mandl LA, Johnson BK, Figgie MP, Boettner F, Lee YY, et al. Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study. J Rheumatol. 2015;42:1123–30.
3. van der Goes MC, Hoes JH, Cramer MJ, van der Veen MJ, van der Werf JH, Bijlsma JW, et al. Identifying factors hampering physical activity in longstanding rheumatoid arthritis: what is the role of glucocorticoid therapy? Clin Exp Rheumatol. 2014;32:155–61.
4. Goodman SM, Bykerk VP, D’Carlo E, Cummings RW, Donlin LT, Orange DE, et al. Flares in Patients with Rheumatoid Arthritis after Total Hip and Total
Knee Arthroplasty: Rates, Characteristics, and Risk Factors. J Rheumatol. 2018; 45:604–11.

5. Iwata T, Ito H, Furu M, Hashimoto M, Fuji T, Ikikawa M, et al. Systemic effects of surgical intervention on disease activity, daily function, and medication in patients with rheumatoid arthritis. Scand J Rheumatol. 2016; 45:356–62.

6. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495–9.

7. Good L, Peterson E, Lisander B. Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesthesia. 2003;90:596–9.

8. Strehl C, van der Goes MC, Bijlsma JW, Jacobs JW, Buttgereit F. Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2017;26:187–95.

9. del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2014;66:264–72.

10. Goodman SM, Figgie MA. Arthroplasty in patients with established rheumatoid arthritis (RA): Mitigating risks and optimizing outcomes. Best Pract Res Clin Rheumatol. 2015;29:268–42.

11. Graudal N, Jürgens G. Similar effects of disease-modifying anti-rheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010; 62:2852–63.

12. Hirschmann MT, Testa E, Amrsl F, Friederich NF. The unhappy total knee arthroplasty (TKA) patient: higher WOMAC and lower KSS in depressed patients prior and after TKA. Knee Surg Sports Traumatol Arthrosc. 2013;21: 2405–11.

13. March LM, Barcenilla AL, Cross MJ, Lapley HM, Parker D, Brooks PM. Costs and outcomes of total hip and knee joint replacement for rheumatoid arthritis. Clin Rheumatol. 2008;27:1235–42.

14. Goodman SM, Springer B, Guyatt G, Abdel MP, Dasu V, George M, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplast. 2017;32:2628–38.

15. Yue C, Wei R, Liu Y. Perioperative systemic steroid for rapid recovery in total knee and hip arthroplasty: a systematic review and meta-analysis of randomized trials. J Orthop Surg Res. 2017;12:100.

16. Goodman SM. Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management. Drugs Aging. 2015;32:361–9.

17. Abbasi M, Mousavi MJ, Jamalzadeh A, Shamshirbande Z, Rezvan MH, Mohammadi H, et al. Strategies toward rheumatoid arthritis therapy: the old and the new. J Cell Physiol. 2019;234:10018–31.

18. Singh JA, Lewallen DG. Better functional and similar pain outcomes in osteoarthritis compared to rheumatoid arthritis after primary total knee arthroplasty: a cohort study. Arthritis Care Res. 2013;65:1936–41.

19. Goodman SM, Mandl LA, Figgie M, Johnson BK, Alexiades M, Ghomrawi H. The use of biologic DMARDs identifies rheumatoid arthritis patients with more optimistic expectations of total knee arthroplasty. J Rheumatol. 2014;41:1017–23.

20. Verhoeven F, Tordi N, Prati C, Demougeot C, Mougin F, Wendling D. Physical activity in patients with rheumatoid arthritis. Jnt Bone Spine. 2016; 83:265–70.

21. Goodman SM, Ramden-Stein DN, Huang W, Zhu R, Figgie MP, Alexiades MA, et al. Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol. 2014;41:1774–80.

22. Lee SA, Kang SB, Chang CB, Chang MJ, Kim YJ, Song MK, et al. Does the severity or cause of preoperative stiffness affect the clinical results and range of motion after total knee arthroplasty? PLoS One. 2018;13:e0205168.

23. White SJW, Ranson WA, Cho B, Cheung ZB, Ye L, Carrillo D, et al. The Effects of Perioperative Steroid Therapy on Perioperative Mortality and Mortality After Adult Spinal Deformity Surgery. Spine Deform. 2019;7:779–87.

24. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JO, Ehrenstein V, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013;173:743–52.

25. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. 2011;13: R139.

26. Aaltonen KJ, Virkki LA, Jämsen E, Sokka T, Konttinen YT, Peltonen R, et al. Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study. Semin Arthritis Rheum. 2013;43:55–62.

27. Roecker Z, Quinlan ND, Browne JA, Werner BC. Risk of Periprosthetic infection following intra-articular corticosteroid injections after total knee arthroplasty. J Arthroplast. 2020;35:1090–4.

28. Namba RS, Inacio MC, Paxton EW. Risk factors associated with deep surgical site infections after primary total knee arthroplasty: an analysis of 56,216 knees. J Bone Joint Surg Am. 2013;95:775–82.

29. Kobayashi S, Niki Y, Harato K, Nagura T, Nakamura M, Matsumoto M. Rheumatoid arthritis patients achieve better satisfaction but lower functional activities as compared to osteoarthritis patients after total knee arthroplasty. J Arthroplast. 2019;34:478–82.e1.

30. Cordtz RL, Zobbe K, Haaggaard P, Kristensen LE, Overgaard S, Odgaard A, et al. Predictors of revision, prosthesis joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers. Ann Rheum Dis. 2018;77:281–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.